Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.
To assess the clinical efficacy and prognostic outcome of neoadjuvant chemotherapy (NACT) plus radical surgery (RS) as front line treatment in patients with FIGO stage III cervical cancer (CC).



In this retrospective study, 52 FIGO stage III CC patients treated from 2005 to 2015 were included. All patients received platinum-based chemotherapy. Patients reporting clinical response or stable disease after NACT underwent to RS and bilateral systematic pelvic lymphadenectomy with or without aortic lymphadenectomy or anterior exenteration. Patients with progressive disease underwent palliative management.



After NACT, clinical response was observed in 23 patients (44 %): 4 (7.7 %) complete and 19 (36.5 %) partial responses, respectively. Also, 15 patients (28.8 %) had stable disease and 14 (26.9 %) showed disease progression. RS was performed in 40 cases (76.9 %): respectively, 28 (70 %) and 7 (17.5 %) underwent type C2 and D radical hysterectomy, while 5 patients (12.5 %) underwent anterior exenteration. At pathological evaluation, 23 patients (57.5 %) had positive pelvic nodes and 4 (10 %) also had positive aortic nodes. In 6 patients (15 %), moderate-severe (G3-G5) complications occurred. A total of 27 patients (67.5 %) received adjuvant therapy: 16 patients (40 %) received chemotherapy, 10 (25 %) received chemoradiation and 1 (2.5 %) received radiotherapy. Disease relapse occurred in 24 cases (60 %). After follow-up period of 60 months, the median OS of the whole population included was 37 months. Among the 40 surgically treated patients, median OS and DFS were 48 and 23 months, respectively.



NACT plus RS represent a valid alternative with acceptable morbidity for patients with stage III CC.
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy. violante.didonato@uniroma1.it.
Violante
V
Di Donato
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Michele Carlo
MC
Schiavi
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Ilary
I
Ruscito
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Virginia Sibilla
VS
Visentin
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Innocenza
I
Palaia
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Claudia
C
Marchetti
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Margherita
M
Fischetti
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Marco
M
Monti
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Ludovico
L
Muzii
Department of Gynecology Obstetrics Sciences and Urologic Sciences, Umberto I, "Sapienza" University of Rome, Rome, Italy.
Pierluigi
P
Benedetti Panici
D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001011:Aorta; D018196:Carcinoma, Adenosquamous / Q000556:secondary / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects; D008197:Lymph Node Excision; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D010385:Pelvic Exenteration / Q000009:adverse effects; D010388:Pelvis; D017671:Platinum Compounds / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000628:therapy*
D017671:Platinum Compounds